Treatment Patterns for Patients with Advanced/Metastatic Cancers by Site-of-Care
- April 27, 2021
- 2 min read
- Suvapun Bunniran, PhD; Yihua Xu, PhD; Cliff Molife, PhD; Radhika Nair, PhD; Yajun Emily Zhu, MS; Gebra Cuyun Carter, PhD; Sheetal Sheth, PharmD, BCOP; Lisa M. Hess, PhD
The objective of this study was to compare treatments, overall survival (OS), and total costs among patients receiving anticancer therapy in hospital outpatient vs physician office settings. This retrospective observational study utilized claims data from a large national health plan to identify patients with advanced/metastatic non–small cell lung cancer (aNSCLC), metastatic colorectal cancer (mCRC), or metastatic breast cancer (mBC) treated in hospital outpatient or physician office settings.
Patients enrolled in Medicare Advantage Prescription Drug or commercial plans for at least 180 days prior to and at least 30 days after start of first-line (1L) therapy were included. Treatments by lines of therapy, OS, and total costs were evaluated by site of care. Eligible patients included 4618 with aNSCLC, 2304 with mCRC, and 1411 with mBC. There were no major differences in 1L, second-line, or third-line therapy by site of care. Patients with aNSCLC in physician office had longer 1L duration (hospital outpatient, 96 days vs physician office, 102 days; P < .01), but there were no differences in duration of therapy by site of care for mBC or mCRC. Costs were higher in the hospital outpatient setting for mCRC and mBC, but there were no differences in OS for any of the cancers. Although patients received similar care in hospital outpatient and physician office settings, the differences in duration of treatment and costs warrant further evaluation.